Tang Capital Management
Tang Capital Management reported 40 stocks worth $2.2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are AUPH (10.1%), SYRE (7.7%) and MIRM (6.6%). Compared with Q1 2026, the fund opened new positions in NVCT, FULC and NNDM, added to AUPH, CELC and CAPR, trimmed SPY, INSM and STOK and sold out of JANX, BIIB and URGN.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  AUPH Aurinia Pharmaceuticals Inc | $221M | 10.1% | 13M | +815K (+7%) | 8 of 8 | |
| 2 |  SYRE Spyre Therapeutics Inc | $168M | 7.7% | 1.9M | No change | 6 of 8 | |
| 3 |  MIRM Mirum Pharmaceuticals Inc | $145M | 6.6% | 1.2M | No change | 8 of 8 | |
| 4 |  KNSA Kiniksa Pharmaceuticals Intl | $145M | 6.6% | 2.3M | No change | 8 of 8 | |
| 5 |  CELC Celcuity Inc | $138M | 6.3% | 1.3M | +265K (+25%) | 4 of 8 | |
| 6 |  CORT Corcept Therapeutics Inc | $130M | 6.0% | 1.5M | No change | 3 of 8 | |
| 7 |  PTCT Ptc Therapeutics Inc | $122M | 5.6% | 1.5M | No change | 8 of 8 | |
| 8 |  LKFT Galapagos NV | $114M | 5.2% | 3.8M | No change | 8 of 8 | |
| 9 |  CAPR Capricor Therapeutics Inc | $98.7M | 4.5% | 4.1M | +700K (+21%) | 4 of 8 | |
| 10 |  TARS Tarsus Pharmaceuticals Inc | $98.7M | 4.5% | 1.6M | +380K (+32%) | 8 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
KALVISTA PHARMACEUTICALS INC | $92.1M | 4.6M |
 JANX Janux Therapeutics Inc | $7M | 500K |
 BIIB Biogen Inc | $6.4M | 35K |
 URGN Urogen Pharma Ltd | $6.3M | 350K |
 ARVN Arvinas Inc | $5.7M | 539K |
🔒 Free account: see all 15.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Tang Capital Management 13F FAQ
What does Tang Capital Management own?
Tang Capital Management reported 40 stocks worth $2.2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are AUPH (10.1%), SYRE (7.7%) and MIRM (6.6%). The table above lists every position in the filing (the top 10 without an account).
What did Tang Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 4 new positions, 7 added to, 4 trimmed and 15 sold out. New positions include NVCT, FULC and NNDM. It sold all of JANX, BIIB and URGN.
When will Tang Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Tang Capital Management's portfolio worth?
The Q2 2026 filing reports $2.2B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.